创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

YUAN Jianglin, YAN Sida, GAO Mohan, XIE Zhao, WEI Qunchao. Research Progress of Membrane-Associated Tyrosine/Threonine 1 Kinase Inhibitors[J]. Progress in Pharmaceutical Sciences, 2025, 49(2): 126-136. DOI: 10.20053/j.issn1001-5094.2025.02.005
Citation: YUAN Jianglin, YAN Sida, GAO Mohan, XIE Zhao, WEI Qunchao. Research Progress of Membrane-Associated Tyrosine/Threonine 1 Kinase Inhibitors[J]. Progress in Pharmaceutical Sciences, 2025, 49(2): 126-136. DOI: 10.20053/j.issn1001-5094.2025.02.005

Research Progress of Membrane-Associated Tyrosine/Threonine 1 Kinase Inhibitors

  • Cyclin E1 (CCNE1 gene coding) amplification, which is present in various malignant tumors, is closely associated with poor clinical outcomes in patients. At present, the treatment methods for CCNE1 amplified tumors are limited. As a member of Wee kinase family, membrane-associated tyrosine/threonine 1 kinase (PKMYT1) is a cell cycle regulatory enzyme that can affect cell mitosis by regulating the phosphorylation of cyclin-dependent kinase 1 (CDK1). It has been reported that there is a synthetic lethal effect between PKMYT1 inhibition and high expression of CCNE1. Therefore, PKMYT1 inhibitors may be a useful approach for the treatment of CCNE1-amplified tumors with good application prospect. This article mainly introduces the mechanism of action of PKMYT1, its relevance to diseases, and the research progress of small molecule PKMYT1 inhibitors, in order to provide some ideas for its further research and clinical application.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return